viventia.com
Pipeline - Viventia Bio Inc.
http://www.viventia.com/products
VICINIUM BLADDER CANCER TRIAL READ MORE. 1) Pending applications extend patent protection to at least 2036.
viventia.com
Stephen Hurly - Viventia Bio Inc.
http://www.viventia.com/about/stephen-hurly
VICINIUM BLADDER CANCER TRIAL READ MORE. Gregory P. Adams, Ph.D. Erick J. Lucera. Glen MacDonald, Ph.D. Arthur DeCillis, MD. President, Chief Executive Officer and Director. Stephen A. Hurly.
viventia.com
VB4-845 (Vicinium) - Viventia Bio Inc.
http://www.viventia.com/products/vb4-845-vinicium
VICINIUM BLADDER CANCER TRIAL READ MORE. VB4-845) Recombinant fusion protein being designed for the treatment of high-grade non-muscle invasive bladder cancer. Vicinium is Viventia’s Phase III product candidate based on the Company’s Targeted Protein Therapeutics platform. Vicinium consists of a single chain anti-EpCAM fragment fused with Pseudomonas. Exotoxin, and is being tested for locoregional treatment of non-muscle invasive bladder cancer (NMIBC). And II clinical trials.
viventia.com
Company overview - Viventia Bio Inc.
http://www.viventia.com/about/company-overview
VICINIUM BLADDER CANCER TRIAL READ MORE. Viventia Bio is developing next generation oncology therapeutics utilizing our proprietary Targeted Protein Therapeutic technology (TPT). Our novel TPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates.
viventia.com
Scientific advisory board - Viventia Bio Inc.
http://www.viventia.com/about/scientific-advisory-board
VICINIUM BLADDER CANCER TRIAL READ MORE.
viventia.com
Board of Directors - Viventia Bio Inc.
http://www.viventia.com/about/leslie-lewis-dan
VICINIUM BLADDER CANCER TRIAL READ MORE. Martin Barkin, M.D., B.Sc., M.A., F.R.C.S.C. Annalisa Jenkins, M.M.B.S., M.R.C.P. Catherine J. Mackey, Ph.D. Executive Chairman and Director. Leslie L. Dan, B.Sc. Phm., M.B.A., C.M.
viventia.com
VB4-847 (Proxinium) - Viventia Bio Inc.
http://www.viventia.com/products/vb4-847-proxinium-1
VICINIUM BLADDER CANCER TRIAL READ MORE. VB4-847) Recombinant fusion protein being designed for the treatment of late-stage squamous cell carcinoma of the head and neck. Proxinium is a Phase III-ready product candidate based on Viventia’s Targeted Protein Therapeutics platform. Proxinium consists of a single chain EpCAM fragment fused with Pseudomonas. Exotoxin, and is being tested for locoregional treatment (via intratumoral injection) of squamous cell carcinoma of the head and neck (SCCHN).
viventia.com
Press Releases - Viventia Bio Inc.
http://www.viventia.com/press-releases
VICINIUM BLADDER CANCER TRIAL READ MORE. Viventia Expands Leadership Team, Names Arthur P. DeCillis, M.D., as Chief Medical Officer. Viventia Reports on Progress of Anti-Cancer Pipeline at PEGS Korea 2015. Viventia’s Targeted Protein Therapeutics (TPTs) have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates. WINNIPEG, Manitoba, and Philadelphia, PA, September 4, 2015. Viventia Recognizes Chairman Leslie Dan's 50 Years of Leadership in Healthcare. Viventia B...
viventia.com
cGMP Manufacturing - Viventia Bio Inc.
http://www.viventia.com/cgmp-manufacturing
VICINIUM BLADDER CANCER TRIAL READ MORE. Viventia has a fully integrated cGMP production facility with designated Fermentation and Purification suites. In addition, a Quality Control laboratory provides environmental monitoring and oversees product release and stability testing. A separate Pharmaceutical Development (PD) unit develops manufacturing processes for cGMP production and analytical test methods for product release testing. Fermentation and purification process development.
viventia.com
Media - Viventia Bio Inc.
http://www.viventia.com/media
VICINIUM BLADDER CANCER TRIAL READ MORE.